MBCOF (Marvel Biosciences) Cyclically Adjusted Revenue per Share: $0.00 (As of Apr. 2026)


MBCOF Marvel Biosciences Corp MBCOF
34 GF Score
Price $0.11
! 1 Warning Sign
View Full Analysis

What is Marvel Biosciences Cyclically Adjusted Revenue per Share?

Marvel Biosciences MBCOF 34 Cyclically Adjusted Revenue per Share is $0.00 as of Apr. 2026. GuruFocus rates MBCOF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Marvel Biosciences's adjusted revenue per share data for the fiscal year that ended in Jul. 2025 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Jul. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-01), Marvel Biosciences's current stock price is $ 0.1103. Marvel Biosciences's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Jul. 2025 was $0.00. Marvel Biosciences's Cyclically Adjusted PS Ratio of today is .


Marvel Biosciences  (OTCPK:MBCOF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Marvel Biosciences Cyclically Adjusted Revenue per Share Related Terms


Marvel Biosciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Marvel Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences Cyclically Adjusted Revenue per Share Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Marvel Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MBCOF vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Marvel Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Cyclically Adjusted PS Ratio falls into.


MBCOF
34GF Score
Marvel Biosciences Corp MBCOF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marvel Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Marvel Biosciences's adjusted Revenue per Share data for the fiscal year that ended in Jul. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Jul. 2025 (Change)*Current CPI (Jul. 2025)
=0/130.2871*130.2871
=0.000

Current CPI (Jul. 2025) = 130.2871.

Marvel Biosciences does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate it.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Marvel Biosciences (MBCOF) has a Cyclically Adjusted Revenue per Share of $0.00 as of Apr. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Marvel Biosciences and its competitors.
Is Marvel Biosciences' Cyclically Adjusted Revenue per Share too high?
Marvel Biosciences' current Cyclically Adjusted Revenue per Share is $0.00. Overall, Marvel Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Marvel Biosciences' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Marvel Biosciences and its competitors. Marvel Biosciences's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Marvel Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current Cyclically Adjusted Revenue per Share is $0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marvel Biosciences Business Description

Other Exchanges MRVL:Canada
Address 505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
34GF Score

Get the complete analysis for MBCOF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price